PHAT

4.6608.27%
DA

David A. Socks

Co-Founder

Mr. David A. Socks is a co-founder and Managing Partner of Mountainfield Venture Partners, LLC. He has been a serial biopharma entrepreneur for nearly several years during which time he has co-founded more than 15 venture-backed companies, leading to eight FDA approved drug products and six NASDAQ IPOs. Prior to Mountainfield, David was a Venture Partner with Frazier Life Sciences. He served as Chief Business Officer of HilleVax, Inc. since January 06, 2021 until 2024 and served as its Chief Financial Officer until January, 2023. He served as a Venture Partner at Frazier Management, L. L.C. since joining in September 19, 2014 until September 2021. Mr. Socks serves as a Director at Eleusis Holdings Ltd., since July 2021 and serves as its Chair. Mr. Socks Co-Found Phathom Pharmaceuticals, Inc. and had served as Treasurer and Secretary since January 2018 until July 2020. He served as a Director of Phathom Pharmaceuticals, Inc since January 2018 until June 03, 2025 and served as its Strategic Advisor since July 2020 until March 2021. He served as President at Phathom Pharmaceuticals, Inc since March 2019. He served as Interim Chief Financial Officer of Phathom Pharmaceuticals, Inc. since December 2019 until July 2020 and served as its Chief Executive Officer since January 2018 until December 2019. Mr. Socks co-founded Arcutis, Inc., Nexcida Therapeutics, Inc., Outpost Medicine, LLC, Passage Bio, Inc., Recida Therapeutics, Inc. and Scout Bio, Inc. Mr. Socks served as Chief Executive Officer of Nexcida Therapeutics, Outpost Medicine and Scout Bio. He served as an Interim Chief Executive Officer at Outpost Medicine, LLC until November 15, 2017. He was CEO of Scout and currently serves as Executive Chairman of Recida and as a Board Member of Outpost. Prior to joining Frazier, Mr. Socks was the President and Chief Operating Officer at Incline Therapeutics, Inc. from 2010 until its sale to The Medicines Company in 2013. He co-founded Incline in 2010. Mr. Socks co-founded Cadence Pharmaceuticals Inc. in 2004 and served as its Senior Vice President of Corporate Development & Strategy from 2004 until 2010 and Vice President of Business Development from May 2004 to March 2008. Mr. Socks serves as an Advisor at Windamere Venture Partners, L. L.C. He served as Senior Vice President of Corporate Development & Strategy at Cadence Pharmaceuticals Inc. since March 2008. Prior to founding Cadence, Mr. Socks was a Venture Partner at Windamere Venture Partners from 2000 to 2004, where he focused on the formation and development of new life science ventures and specialty pharmaceutical companies. While at Windamere, he co-founded and served as the Vice President of Business Development for Kanisa Pharmaceuticals, Vice President of Finance for CelTor Biosystems and was also a Co-Founder of Avera Pharmaceuticals, MiraMedica, Somaxon Pharmaceuticals, SpineWave and Verus Pharmaceuticals. Mr. Socks formerly worked in business development at Neurocrine Biosciences and in the venture capital arm of EFO Holdings, L. P. Previously, he served as a Senior Manager at Kaiser Associates. He serves on the Board of Directors of both Nexcida Therapeutics and North Bridge. He serves as a Director of Outpost Medicine, LLC. He has experience forming and building therapeutics-focused companies. Mr. Socks holds a B. S. from Georgetown University and an M. B.A. from the Stanford Graduate School of Business.

Positions